The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Open accessAbstract
In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to the induction of the deepest possible response. As a result of these advances, a great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sensitivity techniques to detect minimal residual disease (MRD). In 2016, the International Myeloma Working Group (IMWG) updated MM response categories defining MRD-negative responses both in the bone marrow (assessed by next-generation flow cytometry or next-generation sequencing) and outside the bone marrow. MRD is an important factor independently predicting prognosis during MM treatment. Moreover, using novel combination therapies, MRD-negative status can be achieved in a fairly high percentage of patients. However, many questions regarding the clinical use of MRD status remain unanswered. MRD monitoring can guide treatment intensity, although well-designed clinical trials are needed to demonstrate this potential. This mini-review will focus on currently available techniques and data on MRD testing and their potential future applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationHeroux, J., & Gharib, A. M. (2008) · Molecular Imaging in Oncology · doi:10.3109/9781420019957-3 · Cited by 2,187
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045 · cited 3×
“(50) NTE NDMM: - DaraRd arm (368) - Rd arm (369) NGS (10−5 ) Longitudinal Dara-Rd: 24.”
BackgroundDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V. H. J., Pérez-Morán, J.-J., Vidriales, M.-B., García-Sanz, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.29 · Cited by 676
Munshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 477
Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Faham, M., Zheng, J., Moorhead, M., Carlton, V. E. H., Stow, P., Coustan-Smith, E., Pui, C.-H., & Campana, D. (2012) · Blood · doi:10.1182/blood-2012-07-444042 · Cited by 423
Perrot, A., Lauwers-Cances, V., Corre, J., Robillard, N., Hulin, C., Chretien, M.-L., Dejoie, T., Maheo, S., Stoppa, A.-M., Pegourie, B., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858613 · Cited by 417
Rawstron, A. C., Child, J. A., de Tute, R. M., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Feyler, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2119 · Cited by 415
Bladé, J., Fernández de Larrea, C., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 387
Moreau, P., Attal, M., Caillot, D., Macro, M., Karlin, L., Garderet, L., Facon, T., Benboubker, L., Escoffre-Barbe, M., Stoppa, A.-M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2975 · Cited by 326
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Lahuerta, J.-J., Paiva, B., Vidriales, M.-B., Cordón, L., Cedena, M.-T., Puig, N., Martinez-Lopez, J., Rosiñol, L., Gutierrez, N. C., Martín-Ramos, M.-L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2517 · Cited by 317
Korde, N., Roschewski, M., Zingone, A., Kwok, M., Manasanch, E. E., Bhutani, M., Tageja, N., Kazandjian, D., Mailankody, S., Wu, P., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2010 · Cited by 307
Ladetto, M., Brüggemann, M., Monitillo, L., Ferrero, S., Pepin, F., Drandi, D., Barbero, D., Palumbo, A., Passera, R., Boccadoro, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.375 · Cited by 304
Self-citationPaiva, B., Gutiérrez, N. C., Rosiñol, L., Vídriales, M.-B., Montalbán, M.-Á., Martínez-López, J., Mateos, M.-V., Cibeira, M.-T., Cordón, L., Oriol, A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-370460 · Cited by 300
Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., De Rosa, L., Pregno, P., Grasso, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7172 · Cited by 267
Self-citationRoussel, M., Lauwers-Cances, V., Robillard, N., Hulin, C., Leleu, X., Benboubker, L., Marit, G., Moreau, P., Pegourie, B., Caillot, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8164 · Cited by 266
Flores‐Montero, J., de Tute, R., Paiva, B., Perez, J. J., Böttcher, S., Wind, H., Sanoja, L., Puig, N., Lecrevisse, Q., Vidriales, M. B., et al. (2016) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21265 · Cited by 261
Rasche, L., Angtuaco, E., McDonald, J. E., Buros, A., Stein, C., Pawlyn, C., Thanendrarajan, S., Schinke, C., Samant, R., Yaccoby, S., et al. (2017) · Blood · doi:10.1182/blood-2017-03-774422 · Cited by 254
Paiva, B., Martinez-Lopez, J., Vidriales, M.-B., Mateos, M.-V., Montalban, M.-A., Fernandez-Redondo, E., Alonso, L., Oriol, A., Teruel, A.-I., de Paz, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1967 · Cited by 233
Dimopoulos, M. A., San-Miguel, J., Belch, A., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kim, K., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194282 · Cited by 210
Landgren, O., Devlin, S., Boulad, M., & Mailankody, S. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.222 · Cited by 195
Rawstron, A. C., Gregory, W. M., de Tute, R. M., Davies, F. E., Bell, S. E., Drayson, M. T., Cook, G., Jackson, G. H., Morgan, G. J., Child, J. A., et al. (2015) · Blood · doi:10.1182/blood-2014-07-590166 · Cited by 178
Puig, N., Sarasquete, M. E., Balanzategui, A., Martínez, J., Paiva, B., García, H., Fumero, S., Jiménez, C., Alcoceba, M., Chillón, M. C., et al. (2014) · Leukemia · doi:10.1038/leu.2013.217 · Cited by 170
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Paiva, B., Cedena, M., Puig, N., Arana, P., Vídriales, M., Cordón, L., Flores-Montero, J. A., Gutierrez, N. C., Martín-Ramos, M.-L., Martínez‐López, J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705319 · Cited by 162
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
Rasche, L., Alapat, D. V., Kumar, M., Gershner, G. H., McDonald, J., Wardell, C. P., Samant, R., Hemert, R. L. V., Epstein, J., Williams, A. F., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0329-0 · Cited by 158
Pawlyn, C., Fowkes, L. A., Otero, S., Jones, J. R., Boyd, K. D., Davies, F. E., Morgan, G. J., Collins, D. J., Sharma, B., Riddell, A. M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.338 · Cited by 148
Kalina, T., Flores-Montero, J. A., Lécrevisse, Q., Pedreira, C. E., van der Velden, V. H. J., Nováková, M., Mejstříková, E., Hrušák, O., Böttcher, S., Karsch, D., et al. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22581 · Cited by 145
The role of imaging techniques in the management of multiple myeloma
Zamagni, E., & Cavo, M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12007 · Cited by 145
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
Stetler‐Stevenson, M., Paiva, B., Stoolman, L. M., Lin, P., Jorgensen, J. L., Órfão, A., van Dongen, J. J. M., & Rawstron, A. C. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21249 · Cited by 139
Hillengaß, J., Ayyaz, S., Kilk, K., Weber, M., Hielscher, T., Shah, R., Hose, D., Delorme, S., Goldschmidt, H., & Neben, K. (2012) · Haematologica · doi:10.3324/haematol.2012.065359 · Cited by 128
Hillengaß, J., & Landgren, O. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.740559 · Cited by 111
Mazzotti, C., Buisson, L., Mahéo, S., Perrot, A., Chrétien, M., Leleu, X. P., Hulin, C., Manier, S., Hébraud, B., Roussel, M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018025197 · Cited by 103
Gay, F., Cerrato, C., Petrucci, M. T., Zambello, R., Gamberi, B., Ballanti, S., Omedè, P., Palmieri, S., Troia, R., Spada, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8002 · Cited by 91
Self-citationBergen, H. R., Dasari, S., Dispenzieri, A. A., Mills, J. R., Ramírez-Alvarado, M., Tschumper, R. C., Jelinek, D. F., Barnidge, D. R., & Murray, D. L. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.242651 · Cited by 87
High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
Mills, J. R., Barnidge, D. R., Dispenzieri, A. A., & Murray, D. L. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.75 · Cited by 86
Ferrero, S., Ladetto, M., Drandi, D., Cavallo, F., Genuardi, E., Urbano, M. A., Caltagirone, S., Grasso, M., Rossini, F., Guglielmelli, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.219 · Cited by 85
Self-citation11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions
Lapa, C., García‐Velloso, M. J., Lückerath, K., Samnick, S., Schreder, M., Rodríguez‐Otero, P., Schmid, J.-S., Herrmann, K., Knop, S. T., Buck, A. K., et al. (2017) · Theranostics · doi:10.7150/thno.20491 · Cited by 75
Sachpekidis, C., Mosebach, J., Freitag, M. T., Wilhelm, T., Mai, E. K., Goldschmidt, H., Haberkorn, U., Schlemmer, H., Delorme, S., & Dimitrakopoulou‐Strauss, A. (2015) · Europe PMC (PubMed Central) · Cited by 72
Avet‐Loiseau, H., Corre, J., Lauwers‐Cancès, V., Chrétien, M., Robillard, N., Leleu, X. P., Hulin, C., Gentil, C., Arnulf, B., Belhadj, K., et al. (2015) · Blood · doi:10.1182/blood.v126.23.191.191 · Cited by 61
Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R. A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0384-1 · Cited by 56
Korthals, M., Sehnke, N., Kronenwett, R., Bruns, I., Mau, J., Zohren, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.002 · Cited by 54
Lee, N., Moon, S. Y., Lee, J.-H., Park, H., Kong, S.-Y., Bang, S.-M., Lee, J. H., Yoon, S.-S., & Lee, D. S. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.14 · Cited by 52
Interest of Pet Imaging in Multiple Myeloma
Jamet, B., Bailly, C., Carlier, T., Touzeau, C., Nanni, C., Zamagni, E., Barré, L., Michaud, A.-V., Chérel, M., Moreau, P., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00069 · Cited by 52
Martínez‐López, J., Sánchez-Vega, B., Barrio, S., Cuenca, I., Ruiz‐Heredia, Y., Alonso, R., Rapado, I., Marin, C., Cedena, M. ‐., Paiva, B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.58 · Cited by 51
Gu, J., Liu, J., Chen, M., Huang, B., & Li, J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.07.040 · Cited by 49
Thoren, K. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.02.008 · Cited by 45
Gambella, M., Omedè, P., Spada, S., Muccio, V. E., Gilestro, M., Saraci, E., Grammatico, S., Larocca, A., Conticello, C., Bernardini, A., et al. (2018) · Cancer · doi:10.1002/cncr.31854 · Cited by 41
Self-citationMRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Landgren, O., Lu, S. X., & Hultcrantz, M. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.03.001 · Cited by 37
Voorhees, P. M., Rodriguez, C., Reeves, B., Nathwani, N., Costa, L. J., Lutska, Y., Hoehn, D., Pei, H., Ukropec, J., Qi, M., et al. (2018) · Blood · doi:10.1182/blood-2018-151 · Cited by 37
Surrogate endpoints in randomised controlled trials: a reality check
Kumar, S. K., & Rajkumar, S. V. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31711-8 · Cited by 35
Ludwig, H., Greil, R., Masszi, T., Špıčka, I., Shpilberg, O., Hájek, R., Dmoszyńska, A., Paiva, B., Vídriales, M., Esteves, G. V., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13582 · Cited by 32
Single-Cell Analysis of Circulating Tumor Cells
Thiele, J.-A., Pitule, P., Hicks, J. B., & Kühn, P. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9004-7_17 · Cited by 32
Hahn, T., Wallace, P. K., Fraser, R. A., Fei, M., Tario, J. D., Howard, A., Zhang, Y., Blackwell, B., Brunstein, C. G., Efebera, Y. A., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.687 · Cited by 28
Ocio, E. M., Rodríguez‐Otero, P., Bringhen, S., Oliva, S., Nogai, A., Attal, M., Moreau, P., Kanagavel, D., Fitzmaurice, T. F., Wu, J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111244 · Cited by 22
Self-citationMinimal residual disease in multiple myeloma: use of magnetic resonance imaging
Hillengaß, J., Merz, M., & Delorme, S. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.02.001 · Cited by 21
D’Agostino, M., Paoli, L. D., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.008 · Cited by 17
Self-citationAvet‐Loiseau, H., Moreau, P., Attal, M., Hulin, C., Arnulf, B., Corre, J., Garderet, L., Karlin, L., Lambert, J., Macro, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8017 · Cited by 15
Tute, R. M. D., Rawstron, A. C., Cairns, D. A., Pawlyn, C., Davies, F. E., Collett, C., Kaiser, M., Jones, J. R., Waterhouse, A., Striha, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.245.245 · Cited by 14
Minimal residual disease in multiple myeloma 2019
Kunacheewa, C., Lin, P., & Manasanch, E. E. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.71 · Cited by 2
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Chamoli, A., Gosavi, A. S., Shirwadkar, U. P., Wangdale, K. V., Behera, S. K., Kurrey, N. K., Kalia, K., & Mandoli, A. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105451 · Cited by 589
A review in radiomics: Making personalized medicine a reality via routine imaging
Guiot, J., Vaidyanathan, A., Deprez, L., Zerka, F., Danthine, D., Frix, A., Lambin, P., Bottari, F., Tsoutzidis, N., Miraglio, B., et al. (2022) · Medicinal Research Reviews · doi:10.1002/med.21846 · Cited by 337
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Agliardi, G., Liuzzi, A. R., Hotblack, A., De Feo, D., Núñez, N., Stowe, C. L., Friebel, E., Nannini, F., Rindlisbacher, L., Roberts, T. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20599-x · Cited by 305
Metadata
- Authors
- Oliva, S., D'Agostino, M., Boccadoro, M., & Larocca, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-31
- Volume
- 10
- Pages
- 1-1
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3003751935
- Cited by
- 291
- References
- 64
- FWCI
- 35.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.